Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of group C meningococcal capsular polysaccharide conjugate vaccine

A technology of meningococcal and capsular polysaccharides, which is applied to medical preparations containing active ingredients, carrier-bound antigen/hapten components, antibacterial drugs, etc., which can solve high prices, increase vaccine manufacturing costs, and restrict wide application, etc. problems, achieve good stability, reduce hydrolytic denaturation, and cause little harm to the environment and personnel

Inactive Publication Date: 2016-08-24
北京成大天和生物科技有限公司
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

In previous methods for making an antigenically protective composition called Conjugated Meningoceus Vax (CMV) based on sialidase activity, it was found that certain types of polygalacturonic acids were able to attach themselves onto these polymers through their chemical bond instead of being attached directly thereto. These modifications made them more effective at stimulating specific parts of our body's defense system against disease than previously possible due to lack of activation during the manufacturing process. Additionally, they could potentially have potential applications in developing new treatments for diseases caused by pathogens such as Neisseria gonorrhoeae.

Problems solved by technology

This patented technical problem addressed in this patents relates to developing new effective agents or combinations therapies targeting specific areas such as managing blood fever caused by Neisseremia gonorrhexissis, while avoiding the use of potentially dangerous drugs like Cytochrome P450 monoantismines.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of group C meningococcal capsular polysaccharide conjugate vaccine
  • Preparation method of group C meningococcal capsular polysaccharide conjugate vaccine
  • Preparation method of group C meningococcal capsular polysaccharide conjugate vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Describe the present invention below in conjunction with reaction example

[0010] Group C capsular polysaccharides are dissolved to 5-10 mg / ml, add ADH 1-3 times the mass of polysaccharides to the polysaccharide solution, stir and mix well, adjust the pH of the solution to pH 5.5-6.3 with dilute hydrochloric acid; EDAC at a ratio of 0.2 to 0.6 mg / mg, stirred at room temperature and reacted; during the reaction, dilute hydrochloric acid was used to maintain the pH of the solution at 5.5 to 6.3.

[0011] After reacting for 1 to 2 hours, the polysaccharide derivative solution is ultrafiltered with a 30KD ultrafiltration membrane to remove small molecular substances. Store at 2-8°C after filtration with a 0.45 μm filter membrane.

[0012] Weigh the CRM197 protein and dissolve it to 10-20 mg / ml, mix the polysaccharide derivative solution with the CRM197 protein solution so that the polysaccharide-to-protein mass ratio is 1-2 mg / mg, and put it in an ice bath; adjust the pH ...

Embodiment 2

[0015] Compared with the traditional activation method using CNBr or CDAP, the polysaccharide derivatization method adopted in this study has milder conditions and relatively simple operation. However, whether the polysaccharide conjugates of group C prepared by this method can reach or even exceed those prepared by traditional methods in terms of glycoprotein ratio, yield, and free polysaccharide level is also worthy of attention. The detection of the main indicators was carried out, and the detection results were compared.

[0016] Comparison of biochemical properties of conjugates prepared by different methods

[0017] In order to compare with the traditional method, the CDAP-activated polysaccharide method was used as the control method to prepare the conjugate in this study.

[0018] The main operation steps are as follows:

[0019] Preparation of group C polysaccharide-protein conjugates by indirect binding of CDAP-activated polysaccharides to proteins

[0020] Group ...

Embodiment 3

[0031] Study on Stability of Polysaccharide Conjugates of Group C Meningococcal Meningitis

[0032]In view of the possible exposure temperature of 2-8°C and short-term room temperature under the future production conditions, we investigated the storage of the two batches of the original solution at 2-8°C for 3, 6, 8 months and 20-25°C in the above example. The quality stability after 4 weeks and 6 weeks, and the stability of 3 days, 7 days, and 14 days at 37°C in an extreme environment, and compare the two.

[0033] Two batches of conjugated vaccine stock solution samples were stored at 2-8°C for 3 months, 6 months, and 8 months, and after 3 days, 7 days, and 14 days at 37°C, the indicators were tested respectively. The detection method is the same as above, and the test results are shown in the table. 2 and Table 3.

[0034] As shown in Table 2, the polysaccharide content, protein content, and glycoprotein ratio of the two batches of group C conjugate stock solutions did not...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of a group C meningococcal capsular polysaccharide conjugate vaccine. The preparation method comprises the following steps: conducting EDAC catalysis on group C meningococcal capsular polysaccharide and promoting covalent binding of the group C meningococcal capsular polysaccharide to a truss arm ADH (antidiuretic hormone), so that a polysaccharide derivative is prepared; then, promoting covalent binding of the polysaccharide derivative and carrier protein, namely diphtheria toxin avirulent mutant CRM197, under the action of the EDAC catalysis, so that a polysaccharide-protein conjugate is formed; and purifying and filtering the polysaccharide-protein conjugate, so that a stock solution of the group C meningococcal capsular polysaccharide conjugate vaccine is obtained. The vaccine can be used for preventing epidemic cerebrospinal meningitis and complications thereof in infants caused by group C meningococci.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner 北京成大天和生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com